First patients sought for groundbreaking engineered immune cell cancer trial
Disease control
Not yet recruiting
This is the first study in people to test the safety and early effects of an experimental cell therapy called ML261. It is for adults with advanced small cell lung cancer or certain related neuroendocrine cancers that have come back or stopped responding to standard treatments. D…
Phase: PHASE1 • Sponsor: Moonlight Bio, Inc • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC